AN OPEN-LABEL PHASE III, STUDY TO EVALUATE THE SAFETY OF THE COMBINATION (FENOFIBRATE / PRAVASTATIN 160-40 MG) DURING 24 WEEKS, IN HIGH VASCULAR RISK PATIENTS WITH COMBINED HYPERLIPIDEMIA

Trial Profile

AN OPEN-LABEL PHASE III, STUDY TO EVALUATE THE SAFETY OF THE COMBINATION (FENOFIBRATE / PRAVASTATIN 160-40 MG) DURING 24 WEEKS, IN HIGH VASCULAR RISK PATIENTS WITH COMBINED HYPERLIPIDEMIA

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Fenofibrate/pravastatin (Primary)
  • Indications Hyperlipidaemia
  • Focus Adverse reactions; Registrational
  • Acronyms PRAVAFEN SAFETY
  • Sponsors Laboratoires SMB
  • Most Recent Events

    • 26 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top